AMPH
Amphastar Pharmaceuticals, Inc.
Price Chart
Latest Quote
$19.74
+1.04 (+5.56%)
Current Price
| Previous Close | $18.70 |
| Open | $18.86 |
| Day High | $20.14 |
| Day Low | $18.85 |
| Volume | 737,395 |
Stock Information
| Shares Outstanding | 44.09M |
| Total Debt | $686.38M |
| Cash Equivalents | $291.95M |
| Revenue | $720.53M |
| Net Income | $79.23M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $870.39M |
| P/E Ratio | 11.89 |
| EPS (TTM) | $1.66 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.26B |
| Sales | $720.53M |
| Income | $79.23M |
| Book/sh | $17.33 |
| Cash/sh | $6.62 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 2.73 |
| Current Ratio | 3.85 |
| Debt/Eq | 88.75 |
| EPS Growth TTM | -74.60% |
Returns & Margins
| ROA | 5.34% |
| ROE | 10.39% |
| Gross Margin | 47.34% |
| Operating Margin | 7.96% |
| Profit Margin | 11.00% |
Ownership
| Insider Ownership | 29.70% |
| Institutional Ownership | 76.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 6.28 |
| P/S | 1.21 |
| P/B | 1.14 |
Analyst Data
| Recommendation | hold |
| Target Price | $22.83 |
Technical Indicators
| SMA20 | $18.33 |
| SMA50 | $20.14 |
| SMA200 | $24.50 |
| RSI | 77.13 |
| ATR | 0.7479 |
| Shares Float | 32.84M |
| Short Float | 17.94% |
| Short Ratio | 6.27 |
| Volatility | 0.90 |
| Rel Volume | 0.87 |
Performance History
| Week | +4.72% |
| Month | -17.41% |
| Quarter | +2.07% |
| 6 Months | -28.43% |
| YTD | -25.40% |
| Year | -23.67% |
| 3 Years | -55.51% |
| 5 Years | +4.33% |
| 10 Years | +22.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $19.74 | 748,200 |
| 2026-06-04 | $18.70 | 459,200 |
| 2026-06-03 | $18.12 | 509,300 |
| 2026-06-02 | $18.45 | 810,500 |
| 2026-06-01 | $18.42 | 569,700 |
| 2026-05-29 | $18.85 | 849,100 |
| 2026-05-28 | $19.30 | 621,200 |
| 2026-05-27 | $19.10 | 497,100 |
| 2026-05-26 | $18.81 | 670,800 |
| 2026-05-22 | $18.41 | 485,200 |
| 2026-05-21 | $18.16 | 1,657,000 |
| 2026-05-20 | $18.08 | 868,800 |
| 2026-05-19 | $17.82 | 725,100 |
| 2026-05-18 | $17.20 | 866,000 |
| 2026-05-15 | $16.87 | 679,300 |
| 2026-05-14 | $17.30 | 739,100 |
| 2026-05-13 | $18.32 | 971,200 |
| 2026-05-12 | $17.50 | 1,219,600 |
| 2026-05-11 | $18.45 | 1,359,600 |
| 2026-05-08 | $19.00 | 1,983,800 |
| 2026-05-07 | $24.03 | 373,500 |
| 2026-05-06 | $23.90 | 392,800 |
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
đ° Latest News
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
MarketBeat âĸ 2026-06-04T04:02:17Z
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty
Insider Monkey âĸ 2026-06-02T14:10:43Z
3 Stocks Under $50 with Open Questions
StockStory âĸ 2026-05-26T10:51:49Z
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19
Insider Monkey âĸ 2026-05-20T20:43:33Z
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
StockStory âĸ 2026-05-18T18:28:55Z
The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticalsâs Q1 Earnings Call
StockStory âĸ 2026-05-17T17:24:55Z
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment
StockStory âĸ 2026-05-16T09:56:55Z
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings
Simply Wall St. âĸ 2026-05-15T10:40:58Z
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
MarketBeat âĸ 2026-05-14T06:05:46Z
How The Amphastar Pharmaceuticals (AMPH) Narrative Is Shifting As Targets Fall And New Drugs Launch
Simply Wall St. âĸ 2026-05-12T16:16:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $363,830,000 | $358,112,000 | $293,274,000 | $250,127,000 |
| Cost Of Revenue | $363,830,000 | $358,112,000 | $293,274,000 | $250,127,000 |
| Total Revenue | $719,887,000 | $731,967,000 | $644,395,000 | $498,987,000 |
| Operating Revenue | $719,887,000 | $712,814,000 | $593,238,000 | $498,987,000 |
| Expenses | ||||
| Interest Expense | $25,481,000 | $30,343,000 | $27,158,000 | $1,846,000 |
| Total Expenses | $579,484,000 | $526,548,000 | $447,408,000 | $391,490,000 |
| Other Income Expense | $23,000 | $4,076,000 | $-3,929,000 | $9,068,000 |
| Other Non Operating Income Expenses | $23,000 | $4,076,000 | $-3,929,000 | $9,068,000 |
| Net Non Operating Interest Income Expense | $-16,802,000 | $-19,731,000 | $-21,699,000 | $-525,000 |
| Interest Expense Non Operating | $25,481,000 | $30,343,000 | $27,158,000 | $1,846,000 |
| Operating Expense | $215,654,000 | $168,436,000 | $154,134,000 | $141,363,000 |
| Selling And Marketing Expense | $43,885,000 | $37,802,000 | $28,853,000 | $21,531,000 |
| General And Administrative Expense | $85,925,000 | $56,720,000 | $51,540,000 | $45,061,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Net Interest Income | $-16,802,000 | $-19,731,000 | $-21,699,000 | $-525,000 |
| Interest Income | $8,679,000 | $10,612,000 | $5,459,000 | $1,321,000 |
| Normalized Income | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Net Income From Continuing And Discontinued Operation | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Total Operating Income As Reported | $140,403,000 | $205,419,000 | $196,987,000 | $107,497,000 |
| Net Income Common Stockholders | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Net Income | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Net Income Including Noncontrolling Interests | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Net Income Continuous Operations | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $-573,000 | $-1,981,000 | $-1,177,000 |
| Pretax Income | $123,624,000 | $189,764,000 | $171,359,000 | $116,040,000 |
| Interest Income Non Operating | $8,679,000 | $10,612,000 | $5,459,000 | $1,321,000 |
| Operating Income | $140,403,000 | $205,419,000 | $196,987,000 | $107,497,000 |
| Gross Profit | $356,057,000 | $373,855,000 | $351,121,000 | $248,860,000 |
| Per Share | ||||
| Diluted EPS | $2.03 | $3.06 | $2.60 | $1.74 |
| Basic EPS | $2.10 | $3.29 | $2.85 | $1.88 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $212,306,000 | $277,312,000 | $240,294,000 | $146,161,000 |
| Reconciled Depreciation | $63,201,000 | $57,205,000 | $41,777,000 | $28,275,000 |
| EBITDA (Bullshit earnings) | $212,306,000 | $277,312,000 | $240,294,000 | $146,161,000 |
| EBIT | $149,105,000 | $220,107,000 | $198,517,000 | $117,886,000 |
| Diluted Average Shares | $48,215,000 | $52,058,000 | $53,001,000 | $52,427,000 |
| Basic Average Shares | $46,743,000 | $48,429,000 | $48,265,000 | $48,551,000 |
| Diluted NI Availto Com Stockholders | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Tax Provision | $25,530,000 | $29,672,000 | $31,833,000 | $23,477,000 |
| Research And Development | $85,844,000 | $73,914,000 | $73,741,000 | $74,771,000 |
| Selling General And Administration | $129,810,000 | $94,522,000 | $80,393,000 | $66,592,000 |
| Other Gand A | $85,925,000 | $56,720,000 | $51,540,000 | $45,061,000 |
| Minority Interests | - | - | $0 | $0 |
Fetched: 2026-06-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $222,840,000 | $141,638,000 | $26,126,000 | $491,360,000 |
| Total Assets | $1,629,299,000 | $1,577,470,000 | $1,512,912,000 | $741,987,000 |
| Total Non Current Assets | $993,283,000 | $1,043,399,000 | $1,023,312,000 | $363,668,000 |
| Other Non Current Assets | $31,135,000 | $25,992,000 | $25,910,000 | $20,856,000 |
| Non Current Deferred Assets | $42,464,000 | $71,124,000 | $53,252,000 | $38,527,000 |
| Non Current Deferred Taxes Assets | $42,464,000 | $71,124,000 | $53,252,000 | $38,527,000 |
| Goodwill And Other Intangible Assets | $565,965,000 | $590,660,000 | $613,295,000 | $37,298,000 |
| Other Intangible Assets | $562,563,000 | $587,611,000 | $610,079,000 | $34,172,000 |
| Current Assets | $636,016,000 | $534,071,000 | $489,600,000 | $378,319,000 |
| Other Current Assets | $13,152,000 | $18,214,000 | $9,057,000 | $7,563,000 |
| Restricted Cash | $2,435,000 | $2,435,000 | $2,435,000 | $2,435,000 |
| Inventory | $176,890,000 | $153,741,000 | $105,833,000 | $103,584,000 |
| Receivables | $160,727,000 | $138,036,000 | $115,469,000 | $88,975,000 |
| Taxes Receivable | $17,167,000 | $1,747,000 | $526,000 | $171,000 |
| Accounts Receivable | $143,560,000 | $136,289,000 | $114,943,000 | $88,804,000 |
| Allowance For Doubtful Accounts Receivable | $-3,300,000 | $-3,500,000 | $-2,800,000 | $-2,700,000 |
| Gross Accounts Receivable | $146,860,000 | $139,789,000 | $117,743,000 | $91,504,000 |
| Cash Cash Equivalents And Short Term Investments | $282,812,000 | $221,645,000 | $256,806,000 | $175,762,000 |
| Cash And Cash Equivalents | $170,177,000 | $151,609,000 | $144,296,000 | $156,098,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $440,213,000 | $450,255,000 | $445,719,000 | - |
| Total Debt | $656,002,000 | $650,549,000 | $623,642,000 | $102,582,000 |
| Long Term Debt And Capital Lease Obligation | $646,433,000 | $643,511,000 | $619,300,000 | $96,533,000 |
| Long Term Debt | $608,749,000 | $601,630,000 | $589,579,000 | $72,839,000 |
| Current Debt And Capital Lease Obligation | $9,569,000 | $7,038,000 | $4,342,000 | $6,049,000 |
| Current Debt | $1,641,000 | $234,000 | $436,000 | $3,046,000 |
| Other Current Borrowings | $1,641,000 | $234,000 | $436,000 | $3,046,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $840,494,000 | $845,172,000 | $873,491,000 | $213,329,000 |
| Total Non Current Liabilities Net Minority Interest | $682,338,000 | $671,413,000 | $648,084,000 | $118,467,000 |
| Other Non Current Liabilities | $29,979,000 | $20,945,000 | $22,718,000 | $14,565,000 |
| Non Current Deferred Liabilities | $5,926,000 | $6,957,000 | $6,066,000 | $7,369,000 |
| Non Current Deferred Taxes Liabilities | $5,926,000 | $6,957,000 | $6,066,000 | $7,369,000 |
| Current Liabilities | $158,156,000 | $173,759,000 | $225,407,000 | $94,862,000 |
| Payables And Accrued Expenses | $148,587,000 | $166,721,000 | $221,065,000 | $88,813,000 |
| Payables | $32,831,000 | $40,178,000 | $27,047,000 | $25,072,000 |
| Total Tax Payable | $239,000 | $9,664,000 | $1,609,000 | $4,571,000 |
| Income Tax Payable | $239,000 | $9,664,000 | $1,609,000 | $4,571,000 |
| Accounts Payable | $32,592,000 | $30,514,000 | $25,438,000 | $20,501,000 |
| Equity | ||||
| Common Stock Equity | $788,805,000 | $732,298,000 | $639,421,000 | $528,658,000 |
| Total Equity Gross Minority Interest | $788,805,000 | $732,298,000 | $639,421,000 | $528,658,000 |
| Stockholders Equity | $788,805,000 | $732,298,000 | $639,421,000 | $528,658,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,314,000 | $-9,181,000 | $-8,478,000 | $-8,624,000 |
| Other Equity Adjustments | $-5,314,000 | $-9,181,000 | $-8,478,000 | $-8,624,000 |
| Retained Earnings | $666,881,000 | $568,787,000 | $409,268,000 | $271,723,000 |
| Long Term Equity Investment | - | $0 | $527,000 | $2,414,000 |
| Other | ||||
| Treasury Shares Number | $16,134,386 | $13,229,433 | $11,321,313 | $9,998,162 |
| Ordinary Shares Number | $45,645,497 | $47,617,691 | $48,068,881 | $48,112,069 |
| Share Issued | $61,779,883 | $60,847,124 | $59,390,194 | $58,110,231 |
| Tangible Book Value | $222,840,000 | $141,638,000 | $26,126,000 | $491,360,000 |
| Invested Capital | $1,399,195,000 | $1,334,162,000 | $1,229,436,000 | $604,543,000 |
| Working Capital | $477,860,000 | $360,312,000 | $264,193,000 | $283,457,000 |
| Capital Lease Obligations | $45,612,000 | $48,685,000 | $33,627,000 | $26,697,000 |
| Total Capitalization | $1,397,554,000 | $1,333,928,000 | $1,229,000,000 | $601,497,000 |
| Treasury Stock | $408,148,000 | $332,714,000 | $247,431,000 | $189,524,000 |
| Additional Paid In Capital | $535,380,000 | $505,400,000 | $486,056,000 | $455,077,000 |
| Capital Stock | $6,000 | $6,000 | $6,000 | $6,000 |
| Common Stock | $6,000 | $6,000 | $6,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $37,684,000 | $41,881,000 | $29,721,000 | $23,694,000 |
| Current Capital Lease Obligation | $7,928,000 | $6,804,000 | $3,906,000 | $3,003,000 |
| Current Accrued Expenses | $115,756,000 | $126,543,000 | $194,018,000 | $63,741,000 |
| Investments And Advances | $0 | $10,996,000 | $15,212,000 | $2,414,000 |
| Other Investments | $0 | $10,996,000 | $14,685,000 | $0 |
| Goodwill | $3,402,000 | $3,049,000 | $3,216,000 | $3,126,000 |
| Net PPE | $353,719,000 | $344,627,000 | $315,643,000 | $264,573,000 |
| Accumulated Depreciation | $-306,266,000 | $-271,587,000 | $-245,298,000 | $-220,030,000 |
| Gross PPE | $659,985,000 | $616,214,000 | $560,941,000 | $484,603,000 |
| Leases | $46,098,000 | $42,012,000 | $41,686,000 | $31,535,000 |
| Construction In Progress | $24,407,000 | $36,685,000 | $18,676,000 | $50,842,000 |
| Other Properties | $43,152,000 | $47,282,000 | $32,897,000 | $26,307,000 |
| Machinery Furniture Equipment | $342,099,000 | $313,384,000 | $291,427,000 | $237,742,000 |
| Buildings And Improvements | $196,675,000 | $169,429,000 | $168,771,000 | $130,726,000 |
| Land And Improvements | $7,554,000 | $7,422,000 | $7,484,000 | $7,451,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $29,618,000 | $39,423,000 | $24,929,000 | $18,887,000 |
| Work In Process | $40,440,000 | $32,807,000 | $30,822,000 | $37,090,000 |
| Raw Materials | $106,832,000 | $81,511,000 | $50,082,000 | $47,607,000 |
| Other Short Term Investments | $112,635,000 | $70,036,000 | $112,510,000 | $19,664,000 |
| Investmentsin Associatesat Cost | - | - | - | $2,414,000 |
| Minority Interest | - | - | - | - |
Fetched: 2026-06-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $118,983,000 | $172,345,000 | $145,337,000 | $65,147,000 |
| Operating Activities | ||||
| Operating Cash Flow | $156,115,000 | $213,386,000 | $183,503,000 | $89,181,000 |
| Cash Flow From Continuing Operating Activities | $156,115,000 | $213,386,000 | $183,503,000 | $89,181,000 |
| Operating Gains Losses | $2,531,000 | $-2,210,000 | $7,786,000 | $-878,000 |
| Investing Activities | ||||
| Capital Expenditure | $-37,132,000 | $-41,041,000 | $-38,166,000 | $-24,034,000 |
| Investing Cash Flow | $-70,332,000 | $-124,930,000 | $-649,116,000 | $-32,777,000 |
| Cash Flow From Continuing Investing Activities | $-70,332,000 | $-124,930,000 | $-649,116,000 | $-32,777,000 |
| Net Other Investing Changes | $-4,361,000 | $-4,119,000 | $1,390,000 | $-1,372,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-75,586,000 | $-85,458,000 | $-58,144,000 | $-39,909,000 |
| Financing Cash Flow | $-67,425,000 | $-80,953,000 | $454,093,000 | $-26,439,000 |
| Cash Flow From Continuing Financing Activities | $-67,425,000 | $-80,953,000 | $454,093,000 | $-26,439,000 |
| Net Other Financing Charges | $-687,000 | $-816,000 | $-25,079,000 | $-407,000 |
| Net Common Stock Issuance | $-75,586,000 | $-85,458,000 | $-58,144,000 | $-39,909,000 |
| Other | ||||
| Repayment Of Debt | $-223,000 | $-8,263,000 | $-318,658,000 | $-1,781,000 |
| Issuance Of Debt | $6,216,000 | $18,433,000 | $845,000,000 | $0 |
| Interest Paid Supplemental Data | $23,218,000 | $26,811,000 | $17,573,000 | $3,023,000 |
| Income Tax Paid Supplemental Data | $22,710,000 | $40,104,000 | $49,001,000 | $44,442,000 |
| End Cash Position | $170,412,000 | $151,844,000 | $144,531,000 | $156,333,000 |
| Beginning Cash Position | $151,844,000 | $144,531,000 | $156,333,000 | $126,588,000 |
| Effect Of Exchange Rate Changes | $210,000 | $-190,000 | $-282,000 | $-220,000 |
| Changes In Cash | $18,358,000 | $7,503,000 | $-11,520,000 | $29,965,000 |
| Proceeds From Stock Option Exercised | $2,855,000 | $-4,849,000 | $10,974,000 | $15,658,000 |
| Common Stock Payments | $-75,586,000 | $-85,458,000 | $-58,144,000 | $-39,909,000 |
| Net Issuance Payments Of Debt | $5,993,000 | $10,170,000 | $526,342,000 | $-1,781,000 |
| Net Long Term Debt Issuance | $5,993,000 | $10,170,000 | $526,342,000 | $-1,781,000 |
| Long Term Debt Payments | $-223,000 | $-8,263,000 | $-318,658,000 | $-1,781,000 |
| Long Term Debt Issuance | $6,216,000 | $18,433,000 | $845,000,000 | $0 |
| Net Investment Purchase And Sale | $-28,839,000 | $49,230,000 | $-105,934,000 | $-7,792,000 |
| Sale Of Investment | $90,291,000 | $126,022,000 | $38,622,000 | $27,969,000 |
| Purchase Of Investment | $-119,130,000 | $-76,792,000 | $-144,556,000 | $-35,761,000 |
| Net Business Purchase And Sale | $0 | $-129,000,000 | $-506,406,000 | $0 |
| Purchase Of Business | $0 | $-129,000,000 | $-506,406,000 | $0 |
| Net Intangibles Purchase And Sale | $-2,250,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-2,250,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-34,882,000 | $-41,041,000 | $-38,166,000 | $-23,613,000 |
| Purchase Of PPE | $-34,882,000 | $-41,041,000 | $-38,166,000 | $-24,034,000 |
| Change In Working Capital | $-65,971,000 | $-14,547,000 | $-24,209,000 | $-32,177,000 |
| Change In Other Working Capital | $-24,843,000 | $6,834,000 | $-3,319,000 | $-4,555,000 |
| Change In Other Current Liabilities | $-5,609,000 | $-3,750,000 | $-3,589,000 | $-3,154,000 |
| Change In Payables And Accrued Expense | $-4,559,000 | $63,563,000 | $13,237,000 | $-736,000 |
| Change In Payable | $-4,559,000 | $63,563,000 | $13,237,000 | $-736,000 |
| Change In Account Payable | $-4,559,000 | $63,563,000 | $13,237,000 | $-736,000 |
| Change In Prepaid Assets | $-3,530,000 | $-10,726,000 | $-2,728,000 | $-1,854,000 |
| Change In Inventory | $-21,063,000 | $-48,797,000 | $-1,724,000 | $-11,746,000 |
| Change In Receivables | $-6,367,000 | $-21,671,000 | $-26,086,000 | $-10,132,000 |
| Changes In Account Receivables | $-6,367,000 | $-21,671,000 | $-26,086,000 | $-10,132,000 |
| Other Non Cash Items | $3,355,000 | $6,032,000 | $11,399,000 | $466,000 |
| Stock Based Compensation | $27,277,000 | $24,368,000 | $20,242,000 | $17,860,000 |
| Asset Impairment Charge | $0 | $0 | $2,700,000 | $0 |
| Deferred Tax | $27,628,000 | $-16,981,000 | $-13,737,000 | $-15,751,000 |
| Deferred Income Tax | $27,628,000 | $-16,981,000 | $-13,737,000 | $-15,751,000 |
| Depreciation Amortization Depletion | $63,201,000 | $57,205,000 | $41,777,000 | $28,275,000 |
| Depreciation And Amortization | $63,201,000 | $57,205,000 | $41,777,000 | $28,275,000 |
| Amortization Cash Flow | $25,048,000 | $24,718,000 | $12,830,000 | $954,000 |
| Amortization Of Intangibles | $25,048,000 | $24,718,000 | $12,830,000 | $954,000 |
| Depreciation | $38,153,000 | $32,487,000 | $28,947,000 | $27,321,000 |
| Earnings Losses From Equity Investments | $0 | $573,000 | $1,981,000 | $1,177,000 |
| Gain Loss On Investment Securities | $2,492,000 | $-2,792,000 | $5,330,000 | $-2,196,000 |
| Net Income From Continuing Operations | $98,094,000 | $159,519,000 | $137,545,000 | $91,386,000 |
| Sale Of PPE | - | $0 | $0 | $421,000 |
| Gain Loss On Sale Of Business | - | - | $0 | $0 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-06